Global Adrenoleukodystrophy (ALD) Epidemiology Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Adrenoleukodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Adrenoleukodystrophy (ALD) Understanding

Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland.

The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity. There are three basic forms of ALD: neonatal, childhood, and adult-onset. The childhood ALD is the classical and the most severe form leading to total disability or death. It affects only boys because the genetic defect is sex-linked (carried on the X-chromosome). The adult-onset, called AMN is mild, progresses slowly, and usually appears in people aged 21-35 years.

Adrenoleukodystrophy (ALD) Detailed Epidemiology Segmentation

As per the publisher's analysis, in 2017, the total prevalent population of Adrenoleukodystrophy in the 7MM was 55,242. Based on the type of ALD, it was also assessed that majority of the patients suffer from Cerebral ALD (CALD), with 1,160 cases observed in the US, in 2017, while Adrenomyeloneuropathy (AMN) and Addison Disease account for nearly 774, and 314 cases of the total diagnosed male symptomatic ALD population. Out of the total diagnosed male cases, CALD includes 1,160 cases, which is further divided based on age, i.e., Childhood CALD (894 cases), Adolescent CALD (169 cases), and Adult CALD (97 cases) in 2017 in the US.

Among the European five countries, Germany had the highest diagnosed prevalent population of ALD with 1,895 cases, followed by France and the United Kingdom. On the other hand, Italy had the lowest diagnosed prevalent population of 1,126 in 2017.

Scope of the Report

• The report covers the descriptive overview of Adrenoleukodystrophy, explaining its clinical aspects, symptoms, causes, inheritance pattern, pathophysiology, and diagnosis.
• The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Adrenoleukodystrophy.
• The report helps to recognize the growth opportunities in the 7MM countries for the patient population.
• The report provides the segmentation of the disease epidemiology by Total Prevalent Population of Adrenoleukodystrophy in the 7MM, Gender-specific Prevalence of Adrenoleukodystrophy in the 7MM, Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the 7MM, and Type-specific Diagnosed Prevalence of ALD in Males in the 7MM.

Report Highlights

• 11-Year Forecast of Adrenoleukodystrophy epidemiology
• 7MM Coverage
• Total Prevalent Cases of Adrenoleukodystrophy
• Prevalent Cases according to segmentation: Gender-specific prevalence
• Diagnosed cases of Adrenoleukodystrophy according to segmentation: Gender-specific diagnosed prevalence and type-specific diagnosed prevalence of ALD in male

KOL Views

The publisher interview, KOLs and SME's opinion through primary research to fill the data gaps and validate the secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM concerning the patient population of Adrenoleukodystrophy?
• What are the key findings of the Adrenoleukodystrophy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
• What would be the total number of patients of Adrenoleukodystrophy across the 7MM during the forecast period (2017-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the forecast period (2017-2030)?

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Study Period: 2017-2030

Key Topics Covered:

1. Key Insights

2. Executive Summary of Adrenoleukodystrophy (ALD)

3. Adrenoleukodystrophy (ALD): Epidemiology Overview at a Glance

3.1. Total Epidemiology Share (%) Distribution of ALD in 2017

3.2. Total Epidemiology Share (%) Distribution of ALD in 2030

4. Adrenoleukodystrophy: Disease Background and Overview

4.1. Introduction

4.2. Clinical aspects of ALD

4.3. Causes of ALD

4.4. Inheritance pattern of ALD

4.5. ALD-Symptoms

4.6. Pathogenesis and Pathophysiology of ALD

4.7. Diagnosis

4.7.1. ALD Newborn Screening

4.7.2. Tools for evaluating Cerebral ALD

4.7.3. Diagnostic algorithm

4.7.4. HSCT and presymptomatic diagnosis of ALD in Japan

5. Patient Journey

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Epidemiology Methodology

6.3. KOL Views

6.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM

7. United States Epidemiology

7.1. Assumptions and Rationale

7.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States

7.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States

7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States

7.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States

8. EU5 Epidemiology

9. Japan Epidemiology

10. Appendix

10.1. Bibliography

10.2. Report Methodology

11. Publisher Capabilities

For more information about this report visit https://www.researchandmarkets.com/r/5edp00